Karen G Chee, MD
Medical Oncology · Burlingame
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 16
- 5 carriers
- Offices
- 2
- Since medical school
- 25 years
- University of California, Davis School of Medicine, 2001
Offices
2 locations · UCSF Medical Group Business Services · 1,533 clinicians in this group
Looking this up.
Hospitals listed: Mills-Peninsula Medical Center · Sequoia Hospital · Stanford Health Care · UCSF Medical Center. That is not proof they admit you there this week.
Plans that list them
16 plans · 5 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chee’s office at (650) 341-9131 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
16 of 16 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A81314 · Current
Licensed to practise in California · since 2002 · expires 2026-12-31 · University of California, Davis School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
4 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
- Sequoia HospitalRedwood City, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Death rate among surgical inpatients with serious treatable complications: 104.12 (51.8 to 156.44) · 56 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Sequoia Hospital
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 1 better, 4 the same, 0 worse of 5 measures. Readmissions: 3 better, 6 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 104.12 (51.8 to 156.44) · 56 cases | Better | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.95 (0 to 1.98) · 472 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.91 (0.58 to 1.24) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.8 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 72 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.1 · 258 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.5 · 171 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.3 · 81 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 1,231 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.23 (0.01 to 0.44) · 3,018 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.03 to 0.44) · 3,164 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.59 (0.47 to 4.71) · 1,402 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.47 (0.04 to 2.9) · 926 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.68 (0.21 to 3.16) · 1,310 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.54 (4.42 to 14.67) · 978 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.98 (1.61 to 8.36) · 924 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.69 (0.19 to 3.19) · 192 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.57 (0 to 1.43) · 2,501 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.5 · 332 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.702 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.853 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.2 · 67 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 295 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -27.1 · 76 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -22.3 · 304 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -4.6 · 178 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.3 · 180 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 305 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 41 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 29 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.1 (9.7 to 17.7) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 713 cases | No different | Jan 2024 – Dec 2024 |
What patients said (631 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 78% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 82% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 81% |
| Doctors "always" treated them with courtesy and respect | 89% |
| Patients who gave a rating of "9" or "10" (high) | 77% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 77% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 55% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 91% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$2,804,787
Medicare paid this office $2,804,787 for 455 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 292 | $86,490 | $114 |
| Administration of chemotherapy into vein, 1 hour or less | 46 | $54,298 | $137 |
| Long return visit (40+ min) | 100 | $27,643 | $169 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 21 | $21,293 | $172 |
| Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 13 | $20,855 | $6 |
See all 39 services
| Return visit (30+ min) | 292 | $86,490 | $114 |
| Administration of chemotherapy into vein, 1 hour or less | 46 | $54,298 | $137 |
| Long return visit (40+ min) | 100 | $27,643 | $169 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 21 | $21,293 | $172 |
| Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 13 | $20,855 | $6 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 330 | $11,972 | $15 |
| Collection of blood sample from implanted device | 52 | $11,411 | $30 |
| Administration of additional new drug or substance into vein, 1 hour or less | 26 | $11,334 | $67 |
| Short return visit (20+ min) | 105 | $11,215 | $76 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 12 | $11,021 | $75 |
| Injection, aprepitant, 1 mg | 11 | $10,825 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 56 | $10,242 | $70 |
| New patient visit (60+ min) | 50 | $10,187 | $204 |
| Injection of additional new drug or substance into vein | 38 | $8,943 | $16 |
| Injection, leucovorin calcium, per 50 mg | 19 | $6,405 | None |
| Injection of drug or substance under skin or into muscle | 48 | $6,113 | $14 |
| New patient visit (45+ min) | 37 | $5,427 | $147 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 34 | $5,196 | $153 |
| Administration of additional new drug or substance into vein using push technique | 16 | $3,754 | $57 |
| Drawing of blood for a medical problem | 12 | $3,565 | $99 |
| Administration of chemotherapy into vein, each additional hour | 25 | $3,024 | $29 |
| Injection, fluorouracil, 500 mg | 20 | $2,718 | None |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 20 | $2,417 | $20 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 11 | $2,148 | $179 |
| Infusion, normal saline solution , 1000 cc | 63 | $1,594 | None |
| Irrigation of implanted venous access drug delivery device | 19 | $1,576 | $27 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $1,575 | $105 |
| Injection, oxaliplatin, 0.5 mg | 17 | $1,482 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 12 | $1,470 | $61 |
| Influenza vaccine split virus, preservative free | 13 | $1,064 | $82 |
| Injection of drug or substance into vein | 12 | $928 | $39 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 28 | $911 | $29 |
| Infusion into a vein for hydration, each additional hour | 25 | $797 | $12 |
| Collection of blood sample from central venous tube | 15 | $692 | $33 |
| 5% dextrose/water (500 ml = 1 unit) | 25 | $659 | None |
| Administration of influenza virus vaccine | 15 | $580 | $39 |
| Injection, palonosetron hcl, 25 mcg | 11 | $383 | None |
| Injection, atropine sulfate, 0.01 mg | 12 | $140 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 22 | $98 | None |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Collection of blood sample from implanted device | – | 103 | 239 | 201 | 296 | 386 |
| Biopsy and aspiration of bone marrow sample for diagnosis | – | 15 | 16 | 13 | – | 12 |
| Collection of blood sample from central venous tube | – | – | – | – | – | 21 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
455 Original Medicare patients in 2024. Average age 78 · Women 59% · Also on Medicaid 5% · Health risk score 1.88. At or below the middle of the specialty; the typical medical oncology clinician is at 2.11.
Conditions among them: High blood pressure 71% · Cancer 40% · Chronic kidney disease 34% · Diabetes 27% · Coronary heart disease 26% · Atrial fibrillation 26% · Heart failure 22% · COPD 15% · Depression 15% · Stroke 7% · Dementia 5%.
The office billed $25,573,679, Medicare allowed $3,534,180 and paid $2,804,787; for 159,065 services of 111 kinds; $2,479,596 of it was for drugs given in the office and $325,191 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 455 | 159,065 | 78 | 1.88 | $25,573,679 | $2,804,787 |
| 2023 | 402 | 141,965 | 78 | 1.84 | $20,737,098 | $2,339,621 |
| 2022 | 426 | 121,506 | 78 | 1.90 | $20,039,088 | $2,579,621 |
| 2021 | 375 | 102,059 | 77 | 1.88 | $13,116,475 | $1,741,104 |
| 2020 | 357 | 79,090 | 77 | 1.83 | $9,577,961 | $1,303,526 |
| 2019 | 464 | 80,122 | 77 | 2.01 | $3,542,325 | $1,036,582 |
| 2018 | 413 | 72,221 | 76 | 2.09 | $3,418,006 | $1,007,409 |
| 2017 | 373 | 52,801 | 76 | 2.12 | $2,376,509 | $766,818 |
| 2016 | 411 | 53,592 | 76 | 1.98 | $2,237,287 | $698,533 |
| 2015 | 437 | 64,469 | 76 | 2.07 | $2,325,883 | $806,699 |
| 2014 | 388 | 56,685 | 76 | 2.14 | $1,788,372 | $593,667 |
| 2013 | 355 | 27,904 | 76 | 1.83 | $1,387,392 | $443,359 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 29 services
| Return visit (30+ min) | 246 | $69,494 | $111 |
| Administration of chemotherapy into vein, 1 hour or less | 48 | $53,712 | $139 |
| Long return visit (40+ min) | 114 | $33,038 | $159 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 11 | $12,130 | $76 |
| Short return visit (20+ min) | 104 | $10,605 | $73 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 50 | $10,592 | $70 |
| New patient visit (60+ min) | 50 | $9,697 | $194 |
| Administration of additional new drug or substance into vein, 1 hour or less | 20 | $9,565 | $68 |
| Collection of blood sample from implanted device | 43 | $8,517 | $29 |
| Injection of additional new drug or substance into vein | 34 | $8,303 | $16 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 12 | $7,816 | $174 |
| Injection of drug or substance under skin or into muscle | 35 | $6,026 | $14 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 30 | $4,514 | $150 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 11 | $4,418 | $0 |
| Administration of additional new drug or substance into vein using push technique | 14 | $4,265 | $58 |
| New patient visit (45+ min) | 29 | $4,224 | $146 |
| Injection, leucovorin calcium, per 50 mg | 12 | $4,032 | None |
| Administration of chemotherapy into vein, each additional hour | 16 | $1,773 | $29 |
| Injection, fluorouracil, 500 mg | 12 | $1,736 | None |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 12 | $1,678 | $20 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 14 | $1,641 | $66 |
| Infusion, normal saline solution , 1000 cc | 64 | $1,414 | None |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 24 | $987 | $29 |
| Irrigation of implanted venous access drug delivery device | 13 | $908 | $28 |
| Injection of drug or substance into vein | 13 | $782 | $39 |
| Infusion into a vein for hydration, 31-60 minutes | 13 | $754 | $33 |
| 5% dextrose/water (500 ml = 1 unit) | 28 | $550 | None |
| Infusion into a vein for hydration, each additional hour | 13 | $510 | $13 |
| Injection, ondansetron hydrochloride, per 1 mg | 26 | $121 | None |
2022: 22 services
| Return visit (30+ min) | 235 | $71,220 | $111 |
| Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 14 | $66,701 | $6 |
| Administration of chemotherapy into vein, 1 hour or less | 45 | $51,409 | $140 |
| Long return visit (40+ min) | 105 | $35,557 | $163 |
| New patient visit (60+ min) | 61 | $11,643 | $191 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 65 | $10,977 | $62 |
| Short return visit (20+ min) | 103 | $9,472 | $69 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 44 | $7,485 | $170 |
| Administration of additional new drug or substance into vein, 1 hour or less | 16 | $5,546 | $69 |
| Injection of drug or substance under skin or into muscle | 33 | $5,453 | $13 |
| Collection of blood sample from implanted device | 31 | $5,386 | $27 |
| Injection of additional new drug or substance into vein | 25 | $4,847 | $16 |
| New patient visit (45+ min) | 24 | $2,912 | $121 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 11 | $2,040 | $157 |
| Administration of chemotherapy into vein, each additional hour | 15 | $1,895 | $29 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 11 | $1,265 | $70 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 28 | $1,050 | $29 |
| Telephone medical discussion with physician, 11-20 minutes | 13 | $918 | $66 |
| Infusion, normal saline solution , 1000 cc | 59 | $755 | None |
| 5% dextrose/water (500 ml = 1 unit) | 22 | $156 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 20 | $54 | None |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 18 | $22 | None |
2021: 29 services
| Return visit (30+ min) | 205 | $59,337 | $117 |
| Administration of chemotherapy into vein, 1 hour or less | 41 | $47,579 | $153 |
| Long return visit (40+ min) | 117 | $41,598 | $166 |
| Administration of prolonged chemotherapy into vein | 14 | $14,120 | $155 |
| New patient visit (60+ min) | 71 | $13,372 | $188 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 56 | $10,559 | $65 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 46 | $8,538 | $182 |
| Administration of additional new drug or substance into vein, 1 hour or less | 20 | $7,649 | $75 |
| Short return visit (20+ min) | 71 | $7,501 | $77 |
| Collection of blood sample from implanted device | 31 | $6,869 | $29 |
| Injection of additional new drug or substance into vein | 27 | $4,320 | $17 |
| Injection of drug or substance under skin or into muscle | 35 | $3,509 | $13 |
| Telephone medical discussion with physician, 11-20 minutes | 38 | $3,387 | $71 |
| New patient visit (45+ min) | 20 | $3,023 | $151 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 15 | $2,924 | $183 |
| Injection, leucovorin calcium, per 50 mg | 13 | $2,684 | None |
| Administration of chemotherapy into vein, each additional hour | 19 | $2,659 | $32 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 12 | $2,385 | $77 |
| Injection, oxaliplatin, 0.5 mg | 11 | $1,428 | None |
| Irrigation of implanted venous access drug delivery device | 19 | $1,310 | $29 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 13 | $1,248 | $21 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 30 | $1,222 | $31 |
| Injection, fluorouracil, 500 mg | 13 | $909 | None |
| Infusion, normal saline solution , 1000 cc | 55 | $849 | None |
| Telephone medical discussion with physician, 5-10 minutes | 12 | $662 | $51 |
| 5% dextrose/water (500 ml = 1 unit) | 27 | $290 | None |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 30 | $152 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 20 | $51 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 12 | $34 | None |
2020: 24 services
| Return visit (30+ min) | 181 | $42,043 | $95 |
| Administration of chemotherapy into vein, 1 hour or less | 38 | $36,174 | $146 |
| Long return visit (40+ min) | 62 | $17,014 | $136 |
| New patient visit (60+ min) | 63 | $11,482 | $182 |
| Short return visit (20+ min) | 119 | $9,322 | $58 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 50 | $8,313 | $65 |
| Administration of additional new drug or substance into vein, 1 hour or less | 24 | $7,332 | $71 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 38 | $6,958 | $183 |
| New patient visit (45+ min) | 31 | $4,490 | $145 |
| Telephone medical discussion with physician, 11-20 minutes | 52 | $4,302 | $69 |
| Injection of additional new drug or substance into vein | 25 | $4,104 | $17 |
| Injection of drug or substance under skin or into muscle | 27 | $3,635 | $13 |
| Administration of additional new drug or substance into vein using push technique | 13 | $3,453 | $61 |
| Collection of blood sample from implanted device | 15 | $2,720 | $26 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 15 | $2,472 | $165 |
| Telephone medical discussion with physician, 21-30 minutes | 18 | $2,378 | $103 |
| Administration of chemotherapy into vein, each additional hour | 16 | $2,107 | $31 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 11 | $2,033 | None |
| Irrigation of implanted venous access drug delivery device | 13 | $1,066 | $28 |
| Infusion, normal saline solution , 1000 cc | 43 | $564 | None |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 17 | $227 | None |
| 5% dextrose/water (500 ml = 1 unit) | 22 | $175 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 18 | $112 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 13 | $35 | None |
2019: 28 services
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 19 | $71,495 | None |
| Return visit (30+ min) | 221 | $65,650 | $96 |
| Injection, bortezomib, 0.1 mg | 11 | $63,764 | None |
| Administration of chemotherapy into vein, 1 hour or less | 68 | $35,455 | $140 |
| Short return visit (20+ min) | 165 | $16,312 | $66 |
| New patient visit (60+ min) | 91 | $16,155 | $178 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 69 | $11,275 | $64 |
| Injection, palonosetron hcl, 25 mcg | 25 | $8,584 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 53 | $8,278 | $31 |
| Long return visit (40+ min) | 51 | $8,082 | $130 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 39 | $7,165 | $179 |
| Administration of additional new drug or substance into vein, 1 hour or less | 28 | $5,693 | $69 |
| Injection of drug or substance under skin or into muscle | 50 | $4,829 | $16 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 11 | $4,058 | $80 |
| Drawing of blood for a medical problem | 14 | $3,169 | $99 |
| Administration of chemotherapy into vein, each additional hour | 33 | $3,041 | $30 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 13 | $3,011 | None |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 67 | $2,081 | $8 |
| Irrigation of implanted venous access drug delivery device | 23 | $1,993 | $27 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 17 | $1,901 | $70 |
| Advance care planning, first 30 minutes | 11 | $998 | $77 |
| Insertion of needle into vein for collection of blood sample | 72 | $785 | $3 |
| Injection, carboplatin, 50 mg | 15 | $669 | None |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 12 | $413 | $34 |
| Injection, dexamethasone sodium phosphate, 1 mg | 50 | $290 | None |
| Injection, ranitidine hydrochloride, 25 mg | 19 | $214 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 34 | $109 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 19 | $17 | None |
2018: 24 services
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 15 | $90,817 | None |
| Administration of chemotherapy into vein, 1 hour or less | 72 | $46,086 | $145 |
| Return visit (30+ min) | 161 | $45,539 | $96 |
| Short return visit (20+ min) | 204 | $22,505 | $62 |
| Injection, palonosetron hcl, 25 mcg | 17 | $10,419 | None |
| New patient visit (60+ min) | 57 | $10,290 | $181 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 51 | $9,218 | $177 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 55 | $8,675 | $31 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 59 | $8,667 | $65 |
| Long return visit (40+ min) | 42 | $7,322 | $131 |
| Injection of drug or substance under skin or into muscle | 38 | $6,841 | $20 |
| Administration of additional new drug or substance into vein, 1 hour or less | 23 | $6,620 | $70 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 15 | $4,643 | None |
| Injection, docetaxel, 1 mg | 13 | $4,424 | None |
| Administration of chemotherapy into vein, each additional hour | 27 | $2,329 | $31 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 55 | $1,795 | $9 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 12 | $1,714 | $75 |
| Irrigation of implanted venous access drug delivery device | 20 | $1,351 | $29 |
| Advance care planning, first 30 minutes | 11 | $918 | $71 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 18 | $761 | $35 |
| Insertion of needle into vein for collection of blood sample | 56 | $617 | $3 |
| Injection, dexamethasone sodium phosphate, 1 mg | 49 | $283 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 43 | $110 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 11 | $50 | None |
2017: 23 services
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 20 | $90,515 | None |
| Return visit (30+ min) | 154 | $39,079 | $95 |
| Administration of chemotherapy into vein, 1 hour or less | 52 | $26,844 | $141 |
| Short return visit (20+ min) | 171 | $18,362 | $59 |
| New patient visit (60+ min) | 58 | $10,426 | $180 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 59 | $8,634 | $64 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 46 | $8,297 | $180 |
| Injection of drug or substance under skin or into muscle | 35 | $7,653 | $25 |
| Long return visit (40+ min) | 45 | $7,640 | $121 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 43 | $5,247 | $31 |
| Injection, palonosetron hcl, 25 mcg | 12 | $5,178 | None |
| Drawing of blood for a medical problem | 13 | $3,302 | $94 |
| Administration of additional new drug or substance into vein, 1 hour or less | 19 | $3,225 | $67 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $1,767 | $93 |
| Administration of chemotherapy into vein, each additional hour | 21 | $1,419 | $28 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 47 | $1,212 | $10 |
| Advance care planning, first 30 minutes | 12 | $1,096 | $69 |
| Irrigation of implanted venous access drug delivery device | 14 | $806 | $24 |
| Injection, carboplatin, 50 mg | 12 | $497 | None |
| Insertion of needle into vein for collection of blood sample | 50 | $400 | $3 |
| Injection, dexamethasone sodium phosphate, 1 mg | 38 | $143 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 31 | $51 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 13 | $9 | None |
2016: 24 services
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 16 | $63,415 | None |
| Return visit (30+ min) | 134 | $34,825 | $95 |
| Administration of chemotherapy into vein, 1 hour or less | 62 | $30,313 | $140 |
| Short return visit (20+ min) | 217 | $28,240 | $62 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 75 | $11,903 | $64 |
| New patient visit (45+ min) | 58 | $8,329 | $144 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 42 | $8,297 | $180 |
| Injection, palonosetron hcl, 25 mcg | 20 | $7,886 | None |
| Injection of drug or substance under skin or into muscle | 36 | $6,157 | $25 |
| Administration of additional new drug or substance into vein, 1 hour or less | 25 | $5,653 | $65 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 48 | $5,554 | $31 |
| Long return visit (40+ min) | 21 | $3,085 | $134 |
| New patient visit (60+ min) | 13 | $2,474 | $190 |
| Administration of chemotherapy into vein, each additional hour | 24 | $2,354 | $29 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 18 | $1,880 | $72 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $1,760 | $93 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 55 | $1,453 | $10 |
| Irrigation of implanted venous access drug delivery device | 11 | $1,072 | $24 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 25 | $1,047 | $35 |
| Injection, carboplatin, 50 mg | 18 | $1,003 | None |
| Insertion of needle into vein for collection of blood sample | 62 | $500 | $3 |
| Injection, dexamethasone sodium phosphate, 1 mg | 44 | $214 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 36 | $84 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 12 | $9 | None |
2015: 28 services
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 15 | $61,500 | None |
| Administration of chemotherapy into vein, 1 hour or less | 78 | $41,555 | $140 |
| Short return visit (20+ min) | 239 | $38,026 | $65 |
| Return visit (30+ min) | 160 | $37,250 | $95 |
| Injection, palonosetron hcl, 25 mcg | 31 | $13,344 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 66 | $9,711 | $65 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 63 | $7,484 | $31 |
| New patient visit (45+ min) | 49 | $7,119 | $145 |
| Injection of drug or substance under skin or into muscle | 36 | $6,072 | $25 |
| Administration of additional new drug or substance into vein, 1 hour or less | 27 | $5,092 | $65 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 28 | $5,075 | $181 |
| Administration of chemotherapy into vein, each additional hour | 40 | $4,347 | $29 |
| Long return visit (40+ min) | 21 | $3,012 | $131 |
| Injection, zoledronic acid, 1 mg | 12 | $2,987 | None |
| Drawing of blood for a medical problem | 13 | $2,554 | $102 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 74 | $2,489 | $10 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 14 | $2,484 | $69 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 16 | $1,770 | None |
| Administration of additional new drug or substance into vein using push technique | 12 | $1,613 | $65 |
| Irrigation of implanted venous access drug delivery device | 21 | $1,538 | $25 |
| Injection, carboplatin, 50 mg | 17 | $1,014 | None |
| Injection, paclitaxel, 1 mg | 13 | $929 | None |
| Insertion of needle into vein for collection of blood sample | 74 | $714 | $3 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 14 | $487 | $35 |
| Injection, dexamethasone sodium phosphate, 1 mg | 62 | $331 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 44 | $63 | None |
| Injection, ranitidine hydrochloride, 25 mg | 16 | $59 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 18 | $20 | None |
2014: 34 services
| Injection, rituximab, 100 mg | 11 | $88,500 | None |
| Injection, pegfilgrastim, 6 mg | 14 | $65,363 | None |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 14 | $32,720 | None |
| Administration of chemotherapy into vein, 1 hour or less | 77 | $31,787 | $135 |
| Return visit (30+ min) | 107 | $27,248 | $97 |
| Short return visit (20+ min) | 186 | $27,214 | $64 |
| Injection, palonosetron hcl, 25 mcg | 40 | $16,261 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 87 | $12,758 | $64 |
| New patient visit (45+ min) | 52 | $7,684 | $148 |
| Injection, zoledronic acid, 1 mg | 13 | $7,504 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 63 | $6,013 | $30 |
| Administration of additional new drug or substance into vein, 1 hour or less | 33 | $5,102 | $64 |
| Injection of drug or substance under skin or into muscle | 38 | $4,700 | $24 |
| Administration of chemotherapy into vein, each additional hour | 44 | $3,987 | $28 |
| Long return visit (40+ min) | 25 | $3,655 | $126 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 21 | $2,842 | $68 |
| Administration of additional new drug or substance into vein using push technique | 11 | $2,839 | $63 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 85 | $2,361 | $10 |
| New patient visit (60+ min) | 12 | $2,255 | $188 |
| Biopsy of bone marrow | 11 | $1,793 | $163 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 17 | $1,788 | None |
| Irrigation of implanted venous access drug delivery device | 23 | $1,395 | $24 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $1,110 | $93 |
| Injection, carboplatin, 50 mg | 16 | $1,035 | None |
| Aspiration of bone marrow sample for diagnosis | 11 | $793 | $72 |
| Insertion of needle into vein for collection of blood sample | 91 | $703 | $3 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 17 | $590 | $35 |
| Injection, paclitaxel, 30 mg | 12 | $571 | None |
| Short return visit | 11 | $460 | $42 |
| Injection, dexamethasone sodium phosphate, 1 mg | 65 | $294 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 41 | $67 | None |
| Injection, ranitidine hydrochloride, 25 mg | 17 | $44 | None |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 19 | $16 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 15 | $13 | None |
2013: 27 services
| Administration of chemotherapy into vein, 1 hour or less | 63 | $32,530 | $147 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 13 | $28,426 | None |
| Return visit (30+ min) | 106 | $25,874 | $96 |
| Short return visit (20+ min) | 175 | $22,746 | $62 |
| Injection, palonosetron hcl, 25 mcg | 28 | $12,243 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 91 | $12,179 | $62 |
| Administration of additional new drug or substance into vein, 1 hour or less | 33 | $6,330 | $74 |
| New patient visit (45+ min) | 40 | $5,962 | $149 |
| Administration of chemotherapy into vein, each additional hour | 35 | $3,759 | $31 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 38 | $3,565 | $32 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 19 | $3,340 | $176 |
| Injection of drug or substance under skin or into muscle | 28 | $3,230 | $25 |
| Long return visit (40+ min) | 18 | $2,815 | $128 |
| New patient visit (60+ min) | 13 | $2,431 | $187 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 63 | $2,085 | $11 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 12 | $1,868 | None |
| Subsequent nursing facility care with straightforward level of medical decision making, per day 20 minutes or more | 11 | $1,728 | $62 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 11 | $1,640 | $78 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $1,082 | $90 |
| Injection, carboplatin, 50 mg | 19 | $1,069 | None |
| Irrigation of implanted venous access drug delivery device | 12 | $1,011 | $26 |
| Insertion of needle into vein for collection of blood sample | 64 | $662 | $3 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 13 | $507 | $34 |
| Injection, dexamethasone sodium phosphate, 1 mg | 56 | $242 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 39 | $113 | None |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 38 | $48 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 14 | $26 | None |
Drugs they prescribed that Part D paid
$2,865,791
Pharmacies billed $2,865,791 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
512 generic and fewer than 11 brand-name prescriptions · $2,865,791 in drug cost · 62 antibiotic prescriptions to 21 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Brukinsa | 58 | $795,629 | $13,718 |
| Jakafi | 38 | $518,984 | $13,657 |
| Imbruvica | 21 | $378,274 | $18,013 |
| Lorbrena | 12 | $229,144 | $19,095 |
| Ibrance | 11 | $172,984 | $15,726 |
See all 21 drugs
| Brukinsa | 58 | $795,629 | $13,718 |
| Jakafi | 38 | $518,984 | $13,657 |
| Imbruvica | 21 | $378,274 | $18,013 |
| Lorbrena | 12 | $229,144 | $19,095 |
| Ibrance | 11 | $172,984 | $15,726 |
| Imatinib Mesylate | 18 | $59,430 | $3,302 |
| Eliquis | 69 | $50,331 | $729 |
| Xarelto | 34 | $30,679 | $902 |
| Deferasirox | 19 | $2,961 | $156 |
| Hydroxyurea | 37 | $1,066 | $29 |
| Acyclovir | 64 | $912 | $14 |
| Diphenoxylate-Atropine | 19 | $854 | $45 |
| Ondansetron | 56 | $786 | $14 |
| Prochlorperazine Maleate | 45 | $730 | $16 |
| Tamoxifen Citrate | 16 | $584 | $36 |
| Sulfamethoxazole-Trimethoprim | 45 | $269 | $6 |
| Lidocaine-Prilocaine | 21 | $268 | $13 |
| Anastrozole | 14 | $230 | $16 |
| Dexamethasone | 12 | $165 | $14 |
| Loperamide | 12 | $88 | $7 |
| Prednisone | 12 | $61 | $5 |
Year by year
| 2024 | 806 | 144 | None | None | $2,865,791 |
| 2023 | 741 | 150 | None | None | $2,083,893 |
| 2022 | 766 | 140 | 2% (17) | None | $2,381,843 |
| 2021 | 713 | 142 | 4% (30) | None | $1,891,281 |
| 2020 | 837 | 144 | 7% (58) | None | $1,885,165 |
| 2019 | 679 | 127 | 5% (33) | 39% | $2,282,429 |
| 2018 | 713 | 114 | 3% (24) | 33% | $2,032,035 |
| 2017 | 871 | 113 | 3% (27) | 26% | $1,812,750 |
| 2016 | 680 | 120 | 3% (23) | None | $1,449,760 |
| 2015 | 634 | 116 | 7% (45) | 24% | $917,567 |
| 2014 | 477 | 88 | 7% (33) | 19% | $381,988 |
| 2013 | 580 | 102 | 10% (59) | 15% | $320,269 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 20 drugs
| Jakafi | 48 | $646,517 | $13,469 |
| Ibrance | 25 | $368,347 | $14,734 |
| Tagrisso | 12 | $184,189 | $15,349 |
| Promacta | 22 | $159,623 | $7,256 |
| Brukinsa | 11 | $150,897 | $13,718 |
| Xarelto | 41 | $37,712 | $920 |
| Eliquis | 48 | $36,369 | $758 |
| Entecavir | 15 | $11,391 | $759 |
| Hydroxyurea | 42 | $1,764 | $42 |
| Acyclovir | 61 | $1,649 | $27 |
| Anastrozole | 24 | $932 | $39 |
| Prochlorperazine Maleate | 42 | $842 | $20 |
| Ondansetron | 42 | $648 | $15 |
| Dexamethasone | 20 | $535 | $27 |
| Warfarin | 14 | $448 | $32 |
| Tamoxifen Citrate | 14 | $378 | $27 |
| Sulfamethoxazole-Trimethoprim | 38 | $341 | $9 |
| Prednisone | 15 | $167 | $11 |
| Lidocaine-Prilocaine | 12 | $162 | $14 |
| Potassium Chloride | 11 | $87 | $8 |
2022: 19 drugs
| Jakafi | 49 | $614,362 | $12,538 |
| Calquence | 16 | $246,361 | $15,398 |
| Ibrance | 17 | $236,738 | $13,926 |
| Imbruvica | 12 | $180,092 | $15,008 |
| Venclexta | 11 | $149,819 | $13,620 |
| Xarelto | 16 | $23,106 | $1,444 |
| Eliquis | 32 | $21,038 | $657 |
| Hydroxyurea | 35 | $1,892 | $54 |
| Acyclovir | 81 | $1,643 | $20 |
| Dexamethasone | 33 | $1,242 | $38 |
| Prochlorperazine Maleate | 38 | $1,206 | $32 |
| Tamoxifen Citrate | 17 | $910 | $54 |
| Anastrozole | 32 | $739 | $23 |
| Letrozole | 11 | $562 | $51 |
| Ondansetron | 27 | $543 | $20 |
| Sulfamethoxazole-Trimethoprim | 77 | $513 | $7 |
| Prednisone | 22 | $176 | $8 |
| Sertraline | 17 | $44 | $3 |
| Furosemide | 16 | $42 | $3 |
2021: 23 drugs
| Jakafi | 46 | $511,568 | $11,121 |
| Imbruvica | 24 | $332,960 | $13,873 |
| Calquence | 16 | $236,277 | $14,767 |
| Promacta | 15 | $116,427 | $7,762 |
| Gleevec | 12 | $106,799 | $8,900 |
| Intron A | 14 | $29,833 | $2,131 |
| Eliquis | 28 | $21,028 | $751 |
| Xarelto | 12 | $17,912 | $1,493 |
| Imatinib Mesylate | 13 | $7,937 | $611 |
| Anagrelide | 14 | $5,932 | $424 |
| Hydroxyurea | 69 | $2,545 | $37 |
| Tamoxifen Citrate | 19 | $1,733 | $91 |
| Entecavir | 15 | $1,232 | $82 |
| Dexamethasone | 23 | $823 | $36 |
| Ondansetron | 28 | $796 | $28 |
| Anastrozole | 31 | $780 | $25 |
| Acyclovir | 39 | $701 | $18 |
| Prochlorperazine Maleate | 29 | $589 | $20 |
| Letrozole | 11 | $376 | $34 |
| Hydrocodone-Acetaminophen | 12 | $331 | $28 |
| Prednisone | 28 | $263 | $9 |
| Lidocaine-Prilocaine | 12 | $253 | $21 |
| Sulfamethoxazole-Trimethoprim | 28 | $113 | $4 |
2020: 24 drugs
| Imbruvica | 32 | $417,290 | $13,040 |
| Jakafi | 38 | $351,829 | $9,259 |
| Revlimid | 30 | $341,432 | $11,381 |
| Gleevec | 12 | $94,050 | $7,838 |
| Promacta | 11 | $89,064 | $8,097 |
| Abiraterone Acetate | 20 | $48,204 | $2,410 |
| Eliquis | 32 | $22,394 | $700 |
| Xarelto | 20 | $21,211 | $1,061 |
| Anagrelide | 17 | $16,254 | $956 |
| Imatinib Mesylate | 18 | $13,625 | $757 |
| Hydroxyurea | 62 | $3,562 | $57 |
| Anastrozole | 40 | $1,220 | $31 |
| Tamoxifen Citrate | 11 | $1,156 | $105 |
| Ondansetron | 40 | $902 | $23 |
| Dexamethasone | 29 | $896 | $31 |
| Prochlorperazine Maleate | 43 | $820 | $19 |
| Acyclovir | 29 | $653 | $23 |
| Hydrocodone-Acetaminophen | 28 | $629 | $22 |
| Prednisone | 34 | $280 | $8 |
| Oxycodone | 13 | $248 | $19 |
| Gabapentin | 13 | $115 | $9 |
| Venlafaxine Hcl Er | 12 | $97 | $8 |
| Furosemide | 13 | $61 | $5 |
| Sulfamethoxazole-Trimethoprim | 20 | $57 | $3 |
2019: 23 drugs
| Imbruvica | 37 | $462,876 | $12,510 |
| Revlimid | 28 | $295,151 | $10,541 |
| Jakafi | 24 | $290,497 | $12,104 |
| Jadenu | 17 | $216,404 | $12,730 |
| Zytiga | 13 | $149,357 | $11,489 |
| Promacta | 16 | $124,101 | $7,756 |
| Gleevec | 12 | $103,152 | $8,596 |
| Abiraterone Acetate | 17 | $81,225 | $4,778 |
| Eliquis | 28 | $18,739 | $669 |
| Xarelto | 18 | $15,751 | $875 |
| Anagrelide | 28 | $12,945 | $462 |
| Hydroxyurea | 68 | $3,936 | $58 |
| Anastrozole | 41 | $1,065 | $26 |
| Tamoxifen Citrate | 15 | $761 | $51 |
| Dexamethasone | 19 | $450 | $24 |
| Hydrocodone-Acetaminophen | 21 | $437 | $21 |
| Fluoxetine | 13 | $343 | $26 |
| Prochlorperazine Maleate | 14 | $341 | $24 |
| Prednisone | 40 | $314 | $8 |
| Ondansetron | 15 | $278 | $19 |
| Gabapentin | 13 | $190 | $15 |
| Venlafaxine Hcl Er | 15 | $137 | $9 |
| Lorazepam | 13 | $54 | $4 |
2018: 21 drugs
| Jakafi | 34 | $398,422 | $11,718 |
| Tagrisso | 13 | $367,813 | $28,293 |
| Zytiga | 25 | $267,607 | $10,704 |
| Imbruvica | 18 | $246,666 | $13,704 |
| Revlimid | 18 | $165,740 | $9,208 |
| Xarelto | 35 | $18,596 | $531 |
| Anagrelide | 36 | $14,901 | $414 |
| Aromasin | 12 | $14,238 | $1,187 |
| Eliquis | 11 | $5,293 | $481 |
| Hydroxyurea | 80 | $4,173 | $52 |
| Tamoxifen Citrate | 22 | $1,508 | $69 |
| Anastrozole | 39 | $594 | $15 |
| Hydrocodone-Acetaminophen | 15 | $476 | $32 |
| Ondansetron Odt | 13 | $374 | $29 |
| Prednisone | 40 | $311 | $8 |
| Acyclovir | 19 | $284 | $15 |
| Dexamethasone | 18 | $281 | $16 |
| Prochlorperazine Maleate | 30 | $233 | $8 |
| Ondansetron | 18 | $184 | $10 |
| Gabapentin | 15 | $142 | $9 |
| Lorazepam | 14 | $44 | $3 |
2017: 25 drugs
| Jakafi | 37 | $440,910 | $11,916 |
| Imbruvica | 21 | $235,052 | $11,193 |
| Revlimid | 20 | $213,048 | $10,652 |
| Pomalyst | 12 | $174,426 | $14,536 |
| Gilotrif | 12 | $94,001 | $7,833 |
| Leukine | 12 | $92,666 | $7,722 |
| Tarceva | 12 | $84,377 | $7,031 |
| Anagrelide | 60 | $17,502 | $292 |
| Eliquis | 18 | $8,454 | $470 |
| Xarelto | 18 | $7,030 | $391 |
| Exemestane | 12 | $5,259 | $438 |
| Hydroxyurea | 113 | $5,146 | $46 |
| Tamoxifen Citrate | 20 | $1,494 | $75 |
| Anastrozole | 61 | $847 | $14 |
| Acyclovir | 41 | $722 | $18 |
| Hydrocodone-Acetaminophen | 23 | $401 | $17 |
| Fluoxetine | 12 | $355 | $30 |
| Alendronate | 49 | $300 | $6 |
| Gabapentin | 18 | $257 | $14 |
| Ondansetron | 17 | $242 | $14 |
| Prochlorperazine Maleate | 39 | $233 | $6 |
| Ondansetron Odt | 13 | $177 | $14 |
| Dexamethasone | 33 | $160 | $5 |
| Lorazepam | 17 | $42 | $2 |
| Sulfamethoxazole-Trimethoprim | 16 | $24 | $1 |
2016: 19 drugs
| Revlimid | 33 | $272,751 | $8,265 |
| Jakafi | 23 | $248,009 | $10,783 |
| Imbruvica | 17 | $176,465 | $10,380 |
| Leukine | 12 | $92,889 | $7,741 |
| Tarceva | 14 | $91,257 | $6,518 |
| Anagrelide | 67 | $10,269 | $153 |
| Xarelto | 19 | $7,081 | $373 |
| Hydroxyurea | 91 | $2,626 | $29 |
| Tamoxifen Citrate | 39 | $1,495 | $38 |
| Anastrozole | 43 | $842 | $20 |
| Acyclovir | 29 | $539 | $19 |
| Hydrocodone-Acetaminophen | 11 | $420 | $38 |
| Gabapentin | 20 | $270 | $13 |
| Alendronate | 27 | $248 | $9 |
| Dexamethasone | 19 | $200 | $11 |
| Fluoxetine | 12 | $160 | $13 |
| Lorazepam | 11 | $145 | $13 |
| Prochlorperazine Maleate | 18 | $128 | $7 |
| Sulfamethoxazole-Trimethoprim | 13 | $42 | $3 |
2015: 19 drugs
| Revlimid | 18 | $138,629 | $7,702 |
| Gleevec | 12 | $118,022 | $9,835 |
| Jakafi | 11 | $109,103 | $9,918 |
| Xtandi | 11 | $98,773 | $8,979 |
| Tarceva | 14 | $83,992 | $5,999 |
| Enoxaparin | 14 | $15,790 | $1,128 |
| Xarelto | 20 | $6,550 | $327 |
| Anagrelide | 47 | $3,266 | $69 |
| Hydroxyurea | 91 | $2,781 | $31 |
| Tamoxifen Citrate | 36 | $1,091 | $30 |
| Anastrozole | 49 | $924 | $19 |
| Hydrocodone-Acetaminophen | 20 | $672 | $34 |
| Cyclosporine Modified | 13 | $493 | $38 |
| Alendronate | 29 | $331 | $11 |
| Prednisone | 13 | $247 | $19 |
| Acyclovir | 13 | $232 | $18 |
| Prochlorperazine Maleate | 19 | $142 | $7 |
| Dexamethasone | 14 | $129 | $9 |
| Sertraline | 13 | $81 | $6 |
2014: 15 drugs
| Revlimid | 19 | $136,825 | $7,201 |
| Gleevec | 11 | $90,528 | $8,230 |
| Anagrelide | 24 | $10,100 | $421 |
| Xarelto | 17 | $5,168 | $304 |
| Hydroxyurea | 39 | $1,274 | $33 |
| Hydrocodone-Acetaminophen | 19 | $1,028 | $54 |
| Anastrozole | 34 | $968 | $28 |
| Acyclovir | 24 | $428 | $18 |
| Gabapentin | 22 | $356 | $16 |
| Alendronate | 25 | $344 | $14 |
| Prednisone | 22 | $342 | $16 |
| Prochlorperazine Maleate | 19 | $248 | $13 |
| Sertraline | 14 | $104 | $7 |
| Sulfamethoxazole-Trimethoprim | 18 | $102 | $6 |
| Lorazepam | 14 | $73 | $5 |
2013: 17 drugs
| Tarceva | 22 | $116,072 | $5,276 |
| Revlimid | 14 | $95,419 | $6,816 |
| Enoxaparin | 12 | $17,397 | $1,450 |
| Exemestane | 22 | $6,072 | $276 |
| Hydroxyurea | 56 | $1,602 | $29 |
| Venlafaxine Hcl Er | 14 | $1,557 | $111 |
| Anastrozole | 41 | $1,312 | $32 |
| Anagrelide | 20 | $774 | $39 |
| Hydrocodone-Acetaminophen | 31 | $616 | $20 |
| Alendronate | 21 | $422 | $20 |
| Acyclovir | 19 | $359 | $19 |
| Gabapentin | 24 | $330 | $14 |
| Tamoxifen Citrate | 22 | $324 | $15 |
| Warfarin | 22 | $302 | $14 |
| Dexamethasone | 28 | $281 | $10 |
| Prednisone | 22 | $211 | $10 |
| Zolpidem | 15 | $125 | $8 |
Money from drug and device companies
$478 in 2024
| 2024 | 4 | 5 | None | $478 |
| 2023 | 4 | 4 | None | $225 |
| 2022 | 3 | 4 | None | $64 |
| 2021 | 2 | 3 | None | $43 |
| 2020 | 3 | 6 | None | $84 |
| 2019 | 4 | 8 | None | $138 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Epkinly | $151 | 2 payments
|
| Ipsen Biopharmaceuticals | Onivyde | $150 | 1 payment
|
| Celgene | None | $101 | 1 payment
|
| Secura Bio | Copiktra | $76 | 1 payment
|
See all 5 published payments
| Abbvie | Meals · 2024-12-22 | Epkinly | $21 |
| Celgene | Meals · 2024-12-09 | None | $101 |
| Abbvie | Meals · 2024-12-09 | Epkinly | $130 |
| Secura Bio | Meals · 2024-12-07 | Copiktra | $76 |
| Ipsen Biopharmaceuticals | Meals · 2024-10-13 | Onivyde | $150 |
See earlier years (2023, 2022, 2021, 2020, 2019)
2023: $225
| ADC Therapeutics America | None | $143 | 1 payment
|
| Pfizer | Ibrance | $31 | 1 payment
|
| Genzyme | Enjaymo | $29 | 1 payment
|
| PharmaEssentia USA | Besremi | $22 | 1 payment
|
2022: $64
| Janssen Biotech | Imbruvica | $26 | 2 payments
|
| Pharmacyclics LLC an AbbVie | Imbruvica | $21 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Enhertu | $17 | 1 payment
|
2021: $43
| Pfizer | Lorbrena | $29 | 2 payments
|
| Acrotech Biopharma | Beleodaq | $14 | 1 payment
|
2020: $84
| Pfizer | Xalkori | $38 | 3 payments
|
| Janssen Biotech | Imbruvica | $29 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | None | $16 | 1 payment
|
2019: $138
| E.R. Squibb & Sons L.L.C. | None | $43 | 2 payments
|
| Janssen Biotech | Imbruvica | $40 | 3 payments
|
| Seattle Genetics | Adcetris | $36 | 2 payments
|
| Merck Sharp & Dohme | None | $19 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 75.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1487637310
- Licence
- CA A81314California A81314: Current · expires 2026-12-31
- Trained
- University of California, Davis School of Medicine, 2001 · 25 years ago
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 218 De Anza Blvd, San Mateo, CA, 94402
- NPI first listed
- 2005-11-23
- NPI last updated
- 2011-06-02
This is when the NPI record was last certified, not a medical board exam.